Keyword: Catalent

CDMO Catalent is adding packaging equipment to the biologics plant in Indiana it picked up last year in a $950 million deal.

Abzena will invest $20 million in a cell manufacturing facility, and Catalent is spending $2.5 million on a clinical supply facility in China.

Here is some news of note for the week.

Cook Pharmica, a biologics manufacturing company Catalent bought last year, was hit with a Form 483 by the FDA.

CDMO Catalent will pay about $133 million for Boston-based Juniper Pharmaceuticals.

Allergan, which is maneuvering through a host of financial challenges, has landed a new CFO who can help figure out how to pay for the fixes.

Catalent has agreed to pay $950 million to buy Cook Pharmica and its extensive biologics manufacturing operation in Bloomington, Indiana.

New Jersey-based CDMO Catalent signed a deal with US WorldMeds to manufacture lofexidine, an investigational drug used to treat opioid withdrawal.

Thermo Fisher Scientific has completed its $7.2 billion acquisition of CDMO Patheon, weeks after Lonza completed its $5.5 billion buyout of Capsugel.